GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Gross Profit

Novo Nordisk A/S (Novo Nordisk A/S) Gross Profit : $28,444 Mil (TTM As of Dec. 2023)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Gross Profit?

Novo Nordisk A/S's gross profit for the three months ended in Dec. 2023 was $8,171 Mil. Novo Nordisk A/S's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $28,444 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Novo Nordisk A/S's gross profit for the three months ended in Dec. 2023 was $8,171 Mil. Novo Nordisk A/S's Revenue for the three months ended in Dec. 2023 was $9,636 Mil. Therefore, Novo Nordisk A/S's Gross Margin % for the quarter that ended in Dec. 2023 was 84.80%.

Novo Nordisk A/S had a gross margin of 84.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Novo Nordisk A/S was 85.00%. The lowest was 83.20%. And the median was 84.07%.


Novo Nordisk A/S Gross Profit Historical Data

The historical data trend for Novo Nordisk A/S's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Gross Profit Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,162.06 17,335.58 17,800.03 21,145.97 28,749.34

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,671.45 6,499.38 6,758.54 7,014.90 8,171.27

Competitive Comparison of Novo Nordisk A/S's Gross Profit

For the Biotechnology subindustry, Novo Nordisk A/S's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Gross Profit distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Gross Profit falls into.



Novo Nordisk A/S Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Novo Nordisk A/S's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=33982.121 - 5232.779
=28,749

Novo Nordisk A/S's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=9636.42 - 1465.149
=8,171

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $28,444 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Novo Nordisk A/S's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=8,171 / 9636.42
=84.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Novo Nordisk A/S  (NYSE:NVO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Novo Nordisk A/S had a gross margin of 84.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Novo Nordisk A/S Gross Profit Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.